Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40MGF | ISIN: US71902K3032 | Ticker-Symbol:
NASDAQ
01.04.25
17:39 Uhr
0,755 US-Dollar
+0,025
+3,42 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CERO THERAPEUTICS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
CERO THERAPEUTICS HOLDINGS INC 5-Tage-Chart

Aktuelle News zur CERO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:00CERO THERAPEUTICS HOLDINGS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4051
MoCERo Therapeutics Receives FDA Clearance For Second Clinical Trial Of CER-1236 In Solid Tumors1
MoCERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors55SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the...
► Artikel lesen
DoCERo Therapeutics gears up for clinical trial of cancer therapy1
DoCERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing49Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology (ASCO) conference; Continues to be on track to dose first patient in first half of 2025 SOUTH SAN FRANSCISCO...
► Artikel lesen
19.03.CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services72Company continues to improve its market position as it nears launch of its Phase 1 clinical trial in AML SOUTH SAN FRANSCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings...
► Artikel lesen
13.03.CERo Therapeutics präsentiert vielversprechende präklinische Studie zu Eierstockkrebs2
CERO THERAPEUTICS Aktie jetzt für 0€ handeln
13.03.CERo Therapeutics berichtet über positive präklinische Ergebnisse bei Krebsbehandlung1
13.03.CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting89SOUTH SAN FRANSCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the...
► Artikel lesen
06.03.CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays92Company continues toward the initiation of its Phase 1 Clinical Trial in AML for CER-1236 SOUTH SAN FRANSCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:...
► Artikel lesen
05.03.CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-142
06.02.CERo Therapeutics strengthens cash reserves, advances clinical trials2
06.02.CERo Therapeutics Holdings, Inc. Highlights Progress185Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025 SOUTH SAN FRANSCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings...
► Artikel lesen
06.02.CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report1
06.02.CERo Therapeutics to raise $5M via ATM offering2
06.02.CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules2
05.02.CERO THERAPEUTICS HOLDINGS, INC. - S-1/A, General form for registration of securities-
21.01.CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report-
21.01.CERO THERAPEUTICS HOLDINGS, INC. - S-1/A, General form for registration of securities-
07.01.CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report-
Seite:  Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1